Citius Pharmaceuticals (CTXR) to Release Quarterly Earnings on Friday

Citius Pharmaceuticals (NASDAQ:CTXR) is expected to be releasing its Q4 2025 results before the market opens on Friday, December 26th. Analysts expect Citius Pharmaceuticals to post earnings of ($0.24) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, December 23, 2025 at 7:00 AM ET.

Citius Pharmaceuticals Stock Performance

NASDAQ:CTXR opened at $0.78 on Thursday. Citius Pharmaceuticals has a fifty-two week low of $0.63 and a fifty-two week high of $5.95. The firm has a 50-day simple moving average of $1.27 and a two-hundred day simple moving average of $1.32. The firm has a market cap of $13.22 million, a P/E ratio of -0.23 and a beta of 1.51.

Institutional Investors Weigh In On Citius Pharmaceuticals

A hedge fund recently bought a new stake in Citius Pharmaceuticals stock. NewEdge Advisors LLC bought a new position in shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 25,000 shares of the company’s stock, valued at approximately $40,000. NewEdge Advisors LLC owned 0.24% of Citius Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 16.88% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Monday. D. Boral Capital reaffirmed a “buy” rating and set a $6.00 price target on shares of Citius Pharmaceuticals in a research note on Thursday, December 4th. Finally, Wall Street Zen cut Citius Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Friday, September 26th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $6.00.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical?stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital?acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter?related bloodstream infections without catheter removal.